On May 16, a regular general meeting of the Association of Russian Pharmaceutical Manufacturers (ARPM) was held in St. Petersburg. Representatives of the participating companies discussed the current situation in the domestic pharmaceutical industry, the range of acute issues facing the pharmaceutical industry, and the direction of the ARPM for the next six months, dictated by the challenges of the time.
The key moment of the event was the entry of PSK Pharma into the ranks of the ARPM, such a decision was unanimously adopted by the participants of the meeting. The PSK Pharma plant as part of the Rus Biopharm group of companies is an integrated biopharmaceutical enterprise with a full production cycle. This is a Russian developer and manufacturer of a wide range of medicines for the treatment of socially significant diseases, located in the Special Economic Zone «Dubna», in the Moscow region. The priority direction of the company’s activity is drugs for the treatment of asthma and COPD, rheumatoid arthritis and genetically engineered biotechnological drugs. In the areas of asthma and COPD «PSK Pharma» in 2021 and 2022 took the lead in Russia. The company employs more than 450 highly qualified specialists.
Evgenia Shapiro, General Director of PSK Pharma: “We are pleased to become part of an association that for over 20 years has not only represented the interests of the largest Russian pharmaceutical manufacturers, but also implemented a policy to protect the interests of drug consumers. This is consonant with the mission of PSK Pharma — to improve the quality of life and life expectancy of patients. I am sure that the consolidation of the joint efforts of pharmaceutical enterprises — members of the ARPM in this direction is the basis for the drug safety of the country and the provision of citizens with vital and essential medicines. Moreover, only in cooperation it is possible to create domestic full-cycle manufacturing sites, develop new areas, initiate changes in the industry that will ultimately benefit patients.”
Victor Dmitriev, General Director of ARPM, welcoming PSK Pharma, noted: “Today, not only the localization of production in the Russian Federation, but also full-cycle production comes to the fore among the tasks of the industry. This is associated with a number of problems caused by sanctions. PSK Pharma not only successfully overcomes objective difficulties caused by external factors, but also leads in a number of positions. For the ARPM, this new member will become an additional assistant and resource in solving the general problems of the industry. I am confident that our cooperation will be mutually beneficial.”